[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
1. Oksenhendler E, Gerard L, Dubreuil ML, Levy Y, Matheron S, Cazals-Hatem D, Chevret S, Clauvel JP: Intensive chemotherapy (LNHIV-91 regimen) and G-CSF for HIV associated non-Hodgkin's lymphoma. Leuk Lymphoma; 2000 Sep;39(1-2):87-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive chemotherapy (LNHIV-91 regimen) and G-CSF for HIV associated non-Hodgkin's lymphoma.
  • The purpose of the study was to evaluate the safety and long-term efficacy of an intensive chemotherapy regimen associated with G-CSF in HIV-associated non-Hodgkin's lymphoma (NHL).
  • Nineteen tumors were of the Burkitt's type, 23 were large cells, 7 immunoblastic, and 3 anaplastic.
  • Twenty-five patients had stage IV disease (bone marrow involvement in 7, and central nervous system in 9).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulocyte Colony-Stimulating Factor / administration & dosage. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Actuarial Analysis. Adult. Bleomycin / administration & dosage. Bleomycin / toxicity. CD4 Lymphocyte Count. Cyclophosphamide / administration & dosage. Cyclophosphamide / toxicity. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / toxicity. Drug Evaluation. Etoposide / administration & dosage. Etoposide / toxicity. Female. Follow-Up Studies. Hospitalization. Humans. Male. Methotrexate / administration & dosage. Methotrexate / toxicity. Middle Aged. Prednisone / administration & dosage. Prednisone / toxicity. Recurrence. Survival Rate. Treatment Outcome. Vindesine / administration & dosage. Vindesine / toxicity

  • Genetic Alliance. consumer health - HIV.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINDESINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10975387.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] SWITZERLAND
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; RSA8KO39WH / Vindesine; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; LNH 87 protocol
  •  go-up   go-down


2. Pritsa AA, Papazisis KT, Kortsaris AH, Geromichalos GD, Kyriakidis: Antitumor activity of L-asparaginase from Thermus thermophilus. Anticancer Drugs; 2001 Feb;12(2):137-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antitumor activity of L-asparaginase from Thermus thermophilus.
  • The apparent molecular mass of L-asparaginase was found to be 33 kDa by SDS-PAGE, whereas by Sephacryl S-300 superfine column it was found to be 200 kDa, indicating that the enzyme in the native stage acts as hexamer.
  • The antiproliferative activity of the purified L-asparaginase from T. thermiphilus was tested against the following human cell lines: K-562 (chronic myelogenous leukemia), Raji (Burkitt's lymphoma), SK-N-MC (primitive neuroectodermal tumor), HeLa (cervical cancer), BT20 and MCF7 (breast cancers), HT-29 (human colon cancer), and OAW-42 (ovarian cancer).
  • [MeSH-major] Antineoplastic Agents / pharmacology. Asparaginase / pharmacology. Thermus thermophilus / enzymology. Tumor Cells, Cultured / drug effects
  • [MeSH-minor] Cell Division / drug effects. Chromatography, Gel. Dose-Response Relationship, Drug. Electrophoresis, Polyacrylamide Gel. Humans. Molecular Weight

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11261887.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


3. Teo WY, Loh TF, Tan AM: Avoiding dialysis in tumour lysis syndrome: is urate oxidase effective? - a case report and review of literature. Ann Acad Med Singapore; 2007 Aug;36(8):679-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Avoiding dialysis in tumour lysis syndrome: is urate oxidase effective? - a case report and review of literature.
  • INTRODUCTION: Hyperuricaemia in tumour lysis syndrome (TLS) can cause acute renal failure (ARF), necessitating dialysis.
  • CASE REPORT: An 8-year-old boy with stage 3 Burkitt's lymphoma, TLS was successfully treated with hyper-hydration, diuretics and rasburicase, without dialysis.
  • [MeSH-major] Renal Dialysis. Tumor Lysis Syndrome / physiopathology. Urate Oxidase / metabolism
  • [MeSH-minor] Burkitt Lymphoma / complications. Child. Humans. Hyperuricemia / drug therapy. Male. Singapore. Treatment Outcome. Uric Acid / analysis. Uric Acid / blood

  • MedlinePlus Health Information. consumer health - Dialysis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17767339.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Singapore
  • [Chemical-registry-number] 268B43MJ25 / Uric Acid; EC 1.7.3.3 / Urate Oxidase
  • [Number-of-references] 20
  •  go-up   go-down


Advertisement
4. Koshibu-Koizumi J, Akazawa M, Iwamoto T, Takasaki M, Mizuno F, Kobayashi R, Abe A, Tomoda A, Hamatake M, Ishida R: Antitumor activity of a phenoxazine compound, 2-amino-4,4alpha-dihydro-4alpha,7-dimethyl-3H-phenoxazine-3-one against human B cell and T cell lymphoblastoid cell lines: induction of mixed types of cell death, apoptosis, and necrosis. J Cancer Res Clin Oncol; 2002 Jul;128(7):363-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: We studied the antitumor activity of 2-amino-4,4alpha-dihydro-4alpha,7-dimethyl-3H-phenoxazine-3-one (Phx), which was synthesized by the reactions of 2-amino-5-methylphenol with bovine hemoglobin, on human B cell lymphoblastoid cell lines, P3HR-1 and Raji derived from African Burkitt's lymphoma, and the human T cell lymphoblastoid cell line Molt-4.
  • RESULTS: Phx suppressed the viability of P3HR-1, Raji, and Molt-4 cells, though the suppression patterns were different, i.e., Phx suppressed the viability of P3HR-1, Raji, and Molt-4 cells at higher concentrations, while the drug enhanced the viability of Raji cells, but not those of P3HR-1 and Molt-4 cells at lower concentrations.
  • To investigate which type of cell death - apoptosis or necrosis - is induced by Phx, induction of DNA ladder, phosphatidylserine externalization, and propidium iodide-permeable cells were examined in Phx-treated cells.
  • Although Phx did not induce DNA ladder formation, it induced the phosphatidylserine externalization and propidium iodide-permeable cells, suggesting that Phx caused a mixed type of cell death, both apoptosis and necrosis.
  • The population of early stage apoptotic cells was dominant in Raji cells, and that of the late stage apoptotic/necrotic cells was dominant in Molt-4 cells after 72-h treatment with Phx.
  • The population of the early stage apoptotic cells and the late stage apoptotic/necrotic cells was almost equal in P3HR-1 cells in the presence of Phx, though the population of both types of cells increased with time.
  • [MeSH-major] Antineoplastic Agents / toxicity. Apoptosis / drug effects. Cell Death / drug effects. Cell Survival / drug effects. Oxazines / toxicity
  • [MeSH-minor] Annexin A5 / analysis. B-Lymphocytes. Cell Line. Humans. Molecular Structure. Necrosis. T-Lymphocytes. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12136250.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / 2-amino-4,4alpha-dihydro-4alpha,7-dimethyl-3H-phenoxazine-3-one; 0 / Annexin A5; 0 / Antineoplastic Agents; 0 / Oxazines
  •  go-up   go-down


5. Kurokawa M, Andela V, Ghosh S, Barreto JE, Harrington W: Zidovudine: a targeted therapy for endemic Burkitt's lymphoma. East Afr Med J; 2005 Sep;82(9 Suppl):S150-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Zidovudine: a targeted therapy for endemic Burkitt's lymphoma.
  • BACKGROUND: Although cyclophosphamide based regimens can produce remission rates approaching 60 to 80% in endemic Burkitts lymphoma, relapses and refractory disease are fairly common in developing countries, due to advanced stage disease and cost-constraints in the implementation of optimal chemotherapeutic protocols.
  • OBJECTIVE: To evaluate an affordable, tolerable and targeted approach to chemotherapy for endemic Burkitt's lymphoma as would be desirable in resource poor settings such as Africa.
  • METHOD: We present data and review pertinent literature that indicates that the antiviral agent Zidovudine specifically targets this tumour through a unique and novel mechanism.
  • DATA EXTRACTION: A systematic review to identify studies relating to Zidovudine, EBV+ and Burkitt's lymphoma, indicating antiviral agents zidovudine targeting BL in a unique and novel mechanisms.
  • CONCLUSION: Our data suggests that the incorporation of Zidovudine into Burkitt's regimens may enhance tumour kill and abbreviate the duration of treatment necessary for this disease.
  • Furthermore, the addition of the widely available and inexpensive agent hydroxyurea, markedly potentiates the tumorcidal activity of Zidovudine in Epstein Barr virus positive Burkitt's lymphomas.
  • [MeSH-major] Antiviral Agents / therapeutic use. Burkitt Lymphoma / drug therapy. Epstein-Barr Virus Infections / drug therapy. Zidovudine / therapeutic use
  • [MeSH-minor] Africa. Brazil. Developing Countries. Drug Delivery Systems. Gene Targeting. Herpesvirus 4, Human / drug effects. Herpesvirus 4, Human / genetics. Humans. Oncogenes

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. ZIDOVUDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619691.001).
  • [ISSN] 0012-835X
  • [Journal-full-title] East African medical journal
  • [ISO-abbreviation] East Afr Med J
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] Kenya
  • [Chemical-registry-number] 0 / Antiviral Agents; 4B9XT59T7S / Zidovudine
  •  go-up   go-down


6. Schiffer CA: Treatment of high-grade lymphoid malignancies in adults. Semin Hematol; 2001 Oct;38(4 Suppl 10):22-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • High-grade, B-lineage lymphoproliferative disorders can have a leukemic (acute lymphocytic leukemia [ALL] French-American-British [FAB] stage L-3), a lymphomatous (Burkitt's or small noncleaved [SNC]), or often a mixed clinical presentation in adults.
  • Numerous studies show that FAB L-3, Burkitt's lymphoma (BL), and SNC are among the most curable of the multiple leukemia/lymphoma subtypes if treated appropriately.
  • At least 50% of adults with these disorders are cured with the use of short-term intensive chemotherapeutic regimens, with treatment failure a consequence of both drug resistance and an inability of older adults to tolerate the side effects of therapy.
  • [MeSH-major] Lymphoproliferative Disorders / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / blood. Burkitt Lymphoma / complications. Burkitt Lymphoma / drug therapy. Humans. Metabolic Diseases / blood. Metabolic Diseases / etiology. Treatment Outcome. Tumor Lysis Syndrome / blood. Tumor Lysis Syndrome / etiology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 by W.B. Saunders Company.
  • (PMID = 11694948.001).
  • [ISSN] 0037-1963
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 17
  •  go-up   go-down


7. Ahmad N, Zaidi A, Badar F, Maaz AU, Akram MS: Clinical characteristics and outcome analysis of pediatric B-cell non-Hodgkin's lymphoma. Experience with FAB-LMB 96 and UKCCSG B-cell NHL guidelines in a developing country. Asia Pac J Clin Oncol; 2010 Mar;6(1):49-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and outcome analysis of pediatric B-cell non-Hodgkin's lymphoma. Experience with FAB-LMB 96 and UKCCSG B-cell NHL guidelines in a developing country.
  • AIM: To analyze the clinical characteristics of B-cell non-Hodgkin's lymphoma (NHL) patients and the therapeutic efficacy of French-American-British Lymphoma Malins de Burkitt 96 and the recent United Kingdom Children's Cancer Study Group B-cell NHL guidelines in the tertiary care hospital of a developing country.
  • Of these 95 had Burkitt's lymphoma, 22 diffuse large B-cell lymphoma and five had B-cell NHL not otherwise specified.
  • A total of 37 had uric acid >10 mg/dl and 55 had a lactate dehydrogenase level >500; 73 had stage III and 31 had stage IV while only four presented at stage I and 14 at stage II.
  • A total of 45 patients died; 28 due to infection, nine due to tumor lysis syndrome and six of uncontrolled disease.
  • CONCLUSION: Late presentation with advanced disease, poor nutritional status and high risk of exposure to infective agents all contribute to the high mortality in patients treated with intensive protocols in resource-poor countries.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / mortality. Practice Guidelines as Topic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20398038.001).
  • [ISSN] 1743-7563
  • [Journal-full-title] Asia-Pacific journal of clinical oncology
  • [ISO-abbreviation] Asia Pac J Clin Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


8. Fasola FA, Shokunbi WA, Falade AG: Factors determining the outcome of management of patients with Burkitt's lymphoma at the University College Hospital Ibadan, Nigeria--an eleven year review. Niger Postgrad Med J; 2002 Sep;9(3):108-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors determining the outcome of management of patients with Burkitt's lymphoma at the University College Hospital Ibadan, Nigeria--an eleven year review.
  • In recent times, our experience in the chemotherapy of Burkitt's lymphoma patients in Ibadan, Nigeria has been that of poor outcome, hence this study was undertaken to determine the factors leading to the poor results of chemotherapy of Burkitt s lymphoma in Ibadan.
  • A retrospective analysis of Burkitt s Lymphoma patients seen over eleven year period, between January 1987 to December 1997 at the Paediatrics and Haematology Departments of the University College Hospital, Ibadan was carried out.
  • There were 67 patients, mean age 11+5 years (range 4 to 30 years), 42 males, 25 female giving M:F ratio of 1.7:1.
  • Majority of the patients (76.2%) were stage D, only 4.5% were stages A and of the 67 patients, only 57 (83.6%) had chemotherapy, 40 of whom had COAP, 8 had COMP and 9 patients had either cyclophosphamide or cytosar as monotherapy.
  • In this study, we observed a declining overall complete remission rate of 22.8% (compared to 47% in 1979) in Burkitt s Lymphoma patients.
  • The presence of large amount of fake drugs in the Nigerian market may imply that some of the cytotoxic drugs used in these patients could have been fake drugs.
  • We suggest that the government should subsidize the therapy of these patients as well as eradicate the presence of fake drugs in the market, thereby increasing the chances of a cure.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Child. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Drug and Narcotic Control. Female. Humans. Male. Neoplasm Staging. Nigeria / epidemiology. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12501276.001).
  • [ISSN] 1117-1936
  • [Journal-full-title] The Nigerian postgraduate medical journal
  • [ISO-abbreviation] Niger Postgrad Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


9. Tsurusawa M, Katano N, Asami K, Watanabe A, Koizumi S, Miyake M, Kikuta A, Iwai A, Yamamura Y, Kawano Y, Mugishima H, Sekine I, Matsushita T, Horikoshi Y, Kikuchi M, Anami K, Fujimoto T: [Treatment and prognosis of children with relapsed non-Hodgkin's lymphoma--a report from CCLSG-NHL 890 Study. Children's Cancer and Leukemia Study Group (CCLSG)]. Gan To Kagaku Ryoho; 2000 Oct;27(11):1695-702
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment and prognosis of children with relapsed non-Hodgkin's lymphoma--a report from CCLSG-NHL 890 Study. Children's Cancer and Leukemia Study Group (CCLSG)].
  • The reinduction rates and 3-year survival rates (mean +/- SD) were as follows: lymphoblastic lymphoma (LB, n = 9), 44% & 17 +/- 14%; leukemia lymphoma syndrome (LLS, n = 8), 25% & 0%; large cell lymphoma (LC, n = 3) 100% & 67 +/- 27%; Burkitt's lymphoma (B, n = 7) 0% & 0%.
  • Thus, the salvageability of LC lymphoma was good, but the outcome of Burkitt's lymphoma was very poor.
  • CCLSG-NHL960 protocol for LB lymphomas and intensive multiagent regimens for LC lymphomas produced favorable response rates, but the effect of the high-dose Ara-C regimen for Burkitt's lymphoma was not determined.
  • The initial stages of the disease seemed to be associated with the patient outcome: the outcome of the patients in stage IV was inferior to that of patients in stages II or III.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Drug Administration Schedule. Female. Humans. Male. Methotrexate / administration & dosage. Prednisolone / administration & dosage. Prognosis. Recurrence. Retrospective Studies. Salvage Therapy. Survival Rate. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11057320.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Multicenter Study
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; D58G680W0G / pirarubicin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


10. Oberlin O, Brugières L, Patte C, Kalifa C, Vassal G, Valteau-Couanet D, Hartmann O: [What is new in pediatric oncology?]. Arch Pediatr; 2000 Aug;7(8):866-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Quoi de neuf en oncologie pédiatrique?
  • Molecular biology has already been instrumental in more fully categorizing the 'small round-cell tumor' group, and in reclassifying the 'Ewing family' tumors.
  • 1) Burkitt's lymphoma, or an example of the successful de-intensification of treatment; and 2) brain tumors in young children, regarding which the desire to improve the quality of life has led to innovative attempts to replace radiotherapy by chemotherapy.
  • New anti-cancer agents and also chemo- and radiotherapy that spare healthy tissue are also being developed.
  • Gene therapy and molecular biology will play a major role in future therapeutic strategies; and are now at the preclinical trial stage.
  • [MeSH-minor] Brain Neoplasms / therapy. Burkitt Lymphoma / drug therapy. Child. Genetic Predisposition to Disease. Humans. Oncogenes. Quality of Life

  • MedlinePlus Health Information. consumer health - Children's Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10985189.001).
  • [ISSN] 0929-693X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] FRANCE
  •  go-up   go-down


11. Sun XF, Zhen ZJ, Liu DG, Xia Y, Xiang XJ, Chen XQ, Ling JY, Zheng L, Luo WB, Lin H, He YJ, Guan ZZ: [Efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in Chinese children and adolescents]. Ai Zheng; 2007 Dec;26(12):1339-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in Chinese children and adolescents].
  • BACKGROUND & OBJECTIVE: Burkitt's lymphoma is an aggressive non-Hodgkin's lymphoma (NHL) and often involves bone marrow and central nerve system.
  • The efficacy of CHOP regimen on Burkitt's lymphoma is poor.
  • This study was to evaluate the efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in children and adolescents, and observe the survival status.
  • 2006, 31 untreated Burkitt's lymphoma patients aged less than 20 were enrolled.
  • According to St Jude staging system, 1 (3.2%) was at stage I, 6 (19.4%) at stage II, 8 (25.8%) at stage III, 16 (51.6%) at stage IV; 24 (77.4%) were at stage III/IV.
  • According to clinical stage, lactate dehydrogenase (LDH) level and treatment response, these patients were divided into low, moderate and high risk groups.
  • They received modified B-NHL-BFM-90 protocol: cytotoxic drugs such as cyclophosphamide, vincristine, ifosfamide, etoposide, adriamycin, HD-methotrexate, vindesin, dexamethasone, cytarabinec/HD-cytarabine and intrathecal injection.
  • RESULTS: One patient died of tumor lysis syndrome during prophase.
  • Of the 30 patients, 25 (83.3%) achieved complete remission (CR), 3 (10.0%) achieved partial remission (PR), 2 (6.7%) had progressive disease (PD)û 1 had tumor relapse.
  • At a median follow-up of 33 months (range, 3-98 months), the 3-year event-free survival (EFS) rate was 86.0% for all patients, with 100% for stage I/II patients and 82.1% for stage III/IV patients, 100% for low risk group, 92.0% for moderate risk group, and 70.0% for high risk group.
  • CONCLUSIONS: Modified B-NHL-BFM-90 protocol can improve the responses and survival of Burkitt's lymphoma in Chinese children and adolescents, with tolerable toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18076797.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; EC 1.1.1.27 / L-Lactate Dehydrogenase; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


12. Angelova AL, Aprahamian M, Balboni G, Delecluse HJ, Feederle R, Kiprianova I, Grekova SP, Galabov AS, Witzens-Harig M, Ho AD, Rommelaere J, Raykov Z: Oncolytic rat parvovirus H-1PV, a candidate for the treatment of human lymphoma: In vitro and in vivo studies. Mol Ther; 2009 Jul;17(7):1164-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncolytic rat parvovirus H-1PV, a candidate for the treatment of human lymphoma: In vitro and in vivo studies.
  • Autonomous parvoviruses (PVs), in particular the rat parvovirus H-1PV, have emerged as promising anticancer agents.
  • In this study, we demonstrate the capacity of H-1PV for efficiently killing, through necrosis, cell cultures originating from Burkitt's lymphoma (BL), while sparing normal B lymphocytes.
  • Remarkably, parvovirus-based monotherapy efficiently suppressed established BL at an advanced stage in a severe combined immunodeficient (SCID) mouse model of the disease.
  • [MeSH-major] Lymphoma / therapy. Oncolytic Virotherapy / methods. Parvovirus / physiology
  • [MeSH-minor] Animals. Cell Line, Tumor. Cells, Cultured. Humans. Lymphoma, B-Cell / therapy. Mice. Mice, SCID. Necrosis / virology. Rats. Virus Replication / genetics

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • HAL archives ouvertes. Full text from .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1358-64 [17873116.001]
  • [Cites] J Virol. 2007 Apr;81(8):4186-98 [17287256.001]
  • [Cites] Cancer Invest. 2008 May;26(4):401-6 [18443961.001]
  • [Cites] Clin Cancer Res. 2009 Jan 15;15(2):511-9 [19147756.001]
  • [Cites] Cancer Res. 1989 Jun 15;49(12):3203-8 [2541900.001]
  • [Cites] Virus Res. 1990 Jun;16(2):211-23 [2385960.001]
  • [Cites] Virus Res. 1999 Dec 15;65(2):161-74 [10581389.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 1:113-6 [10707791.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 9;97(10):5522-7 [10792046.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1392-8 [11222385.001]
  • [Cites] Cancer Gene Ther. 2001 Mar;8(3):158-67 [11332986.001]
  • [Cites] Int J Hematol. 2001 Feb;73(2):236-44 [11372738.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3746-54 [11389012.001]
  • [Cites] Cancer Gene Ther. 2002 May;9(5):432-42 [11961666.001]
  • [Cites] BMC Microbiol. 2002 Jul 23;2:20 [12137568.001]
  • [Cites] Blood. 2002 Dec 1;100(12):4146-53 [12393565.001]
  • [Cites] J Virol. 2003 Mar;77(6):3851-8 [12610161.001]
  • [Cites] Intervirology. 1975;5(6):319-34 [181343.001]
  • [Cites] Antimicrob Agents Chemother. 1979 Mar;15(3):420-7 [464569.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Apr;80(7):1987-91 [6300885.001]
  • [Cites] Int J Cancer. 1985 Apr 15;35(4):435-41 [2985508.001]
  • [Cites] Cancer Genet Cytogenet. 1986 Feb 1;20(1-2):39-52 [3455861.001]
  • [Cites] Leuk Res. 1986;10(5):487-500 [3713248.001]
  • [Cites] J Virol. 1989 May;63(5):2152-8 [2495371.001]
  • [Cites] EMBO J. 1991 Oct;10(10):2879-87 [1915267.001]
  • [Cites] J Virol Methods. 1991 Aug;33(3):233-51 [1783673.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8702-6 [8378352.001]
  • [Cites] J Virol. 1993 Nov;67(11):6768-77 [8411380.001]
  • [Cites] EMBO J. 1990 Sep;9(9):2989-95 [2167840.001]
  • [Cites] Virus Genes. 1991 Apr;5(2):147-56 [1647567.001]
  • [Cites] J Virol. 1994 Mar;68(3):1397-406 [8107203.001]
  • [Cites] J Virol. 1994 Oct;68(10):6446-53 [8083981.001]
  • [Cites] J Virol. 1995 Sep;69(9):5506-15 [7636996.001]
  • [Cites] Cell Growth Differ. 1995 Jul;6(7):781-7 [7547499.001]
  • [Cites] N Engl J Med. 1997 Aug 21;337(8):529-34 [9262496.001]
  • [Cites] Int J Cancer. 1998 Feb 9;75(4):584-9 [9466660.001]
  • [Cites] J Virol. 1998 Nov;72(11):8893-903 [9765434.001]
  • [Cites] Leukemia. 1998 Dec;12(12):2029-33 [9844934.001]
  • [Cites] Lancet. 1964 Feb 1;1(7327):238-40 [14086209.001]
  • [Cites] J Virol. 2005 May;79(10):6005-22 [15857987.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:260-6 [16304390.001]
  • [Cites] J Vet Med B Infect Dis Vet Public Health. 2005 Sep-Oct;52(7-8):327-30 [16316394.001]
  • [Cites] Int J Cancer. 2007 Mar 15;120(6):1364-71 [17154174.001]
  • [Cites] Leukemia. 2008 Feb;22(2):361-9 [18046450.001]
  • (PMID = 19367260.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2835199
  •  go-up   go-down


13. Kenney S: Theodore E. Woodward Award: development of novel, EBV-targeted therapies for EBV-positive tumors. Trans Am Clin Climatol Assoc; 2006;117:55-73; discussion 73-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In mouse models for EBV-positive tumors, the combination of lytic-inducing chemotherapy and ganciclovir is much more effective than either agent alone for treating tumors.
  • Anti-CD70 monoclonal antibody inhibits the growth of CD70-positive (but not CD70-negative) Burkitt's lymphomas in SCID mice.
  • Finally, while completely lytic EBV infection is clearly incompatible with tumor cell growth, we recently discovered that small numbers of lytically-infected cells actually promote the growth of EBV-immortalized lymphocytes in SCID mice, through the release of paracrine growth factors as well as angiogenic factors.
  • Thus, agents that prevent the earliest stage of lytic EBV infection (such as fatty acid synthase inhibitors), rather than the later stage of viral replication, might also be useful in the treatment of early-stage EBV-positive tumors.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Infect Dis. 1991 Jun;163(6):1341-3 [1645383.001]
  • [Cites] J Clin Invest. 1991 Jul;88(1):239-47 [1647416.001]
  • [Cites] J Virol. 1991 Dec;65(12):7073-7 [1658397.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1890-3 [1371884.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1992;62(1):55-9 [1352076.001]
  • [Cites] J Virol Methods. 1992 Jul;38(1):123-30 [1322927.001]
  • [Cites] J Virol. 1993 Apr;67(4):2014-25 [8445720.001]
  • [Cites] Virology. 1993 Aug;195(2):463-74 [8393235.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):9150-4 [8415670.001]
  • [Cites] Blood. 1995 Jun 15;85(12):3423-30 [7780129.001]
  • [Cites] J Infect. 1995 Nov;31(3):189-94 [8586837.001]
  • [Cites] Cancer Res. 1996 Mar 1;56(5):969-72 [8640787.001]
  • [Cites] Mod Pathol. 1996 Jun;9(6):621-30 [8782198.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1739-44 [8939871.001]
  • [Cites] J Immunol. 1997 May 1;158(9):4045-51 [9126962.001]
  • [Cites] Transplantation. 1997 Sep 27;64(6):848-52 [9326409.001]
  • [Cites] J Gen Virol. 2003 Apr;84(Pt 4):965-74 [12655098.001]
  • [Cites] J Infect Dis. 2003 May 15;187(10):1571-80 [12721937.001]
  • [Cites] J Virol. 2003 Jun;77(11):6546-50 [12743312.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5122-30 [12910249.001]
  • [Cites] J Infect Dis. 2003 Sep 15;188(6):883-90 [12964120.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10989-94 [12947043.001]
  • [Cites] J Virol. 2004 Feb;78(4):1893-902 [14747554.001]
  • [Cites] J Virol. 2004 Apr;78(8):4197-206 [15047835.001]
  • [Cites] Nature. 1978 Nov 16;276(5685):270-2 [213727.001]
  • [Cites] Scand J Infect Dis. 1999;31(6):543-7 [10680982.001]
  • [Cites] Microbes Infect. 2000 Feb;2(2):115-20 [10742683.001]
  • [Cites] Clin Infect Dis. 2000 May;30(5):757-61 [10816144.001]
  • [Cites] Curr Opin Pediatr. 2000 Jun;12(3):263-8 [10836164.001]
  • [Cites] J Virol. 2000 Jul;74(13):5810-8 [10846060.001]
  • [Cites] EMBO J. 2000 Jun 15;19(12):3080-9 [10856251.001]
  • [Cites] J Virol. 2000 Jul;74(14):6675-9 [10864684.001]
  • [Cites] N Engl J Med. 2000 Aug 17;343(7):481-92 [10944566.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5781-8 [11059774.001]
  • [Cites] EMBO J. 2000 Dec 15;19(24):6742-50 [11118209.001]
  • [Cites] Virology. 2001 Feb 15;280(2):183-98 [11162833.001]
  • [Cites] Blood. 2001 Mar 15;97(6):1590-7 [11238096.001]
  • [Cites] Transpl Infect Dis. 2001 Jun;3(2):97-103 [11395975.001]
  • [Cites] Antimicrob Agents Chemother. 2001 Jul;45(7):2082-91 [11408227.001]
  • [Cites] Transpl Infect Dis. 2001 Sep;3(3):177-85 [11493400.001]
  • [Cites] Curr Opin Oncol. 2001 Sep;13(5):360-7 [11555713.001]
  • [Cites] J Infect Dis. 2001 Dec 15;184(12):1499-507 [11740724.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):437-42 [11752411.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1920-6 [11912175.001]
  • [Cites] J Gen Virol. 2002 May;83(Pt 5):1013-23 [11961255.001]
  • [Cites] J Heart Lung Transplant. 2002 May;21(5):547-54 [11983544.001]
  • [Cites] Transplant Proc. 2002 May;34(3):948-9 [12034254.001]
  • [Cites] J Virol. 2002 Nov;76(21):10951-9 [12368338.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Sep;77(9):5163-6 [6254061.001]
  • [Cites] J Virol. 1985 Aug;55(2):286-97 [2991556.001]
  • [Cites] Trends Microbiol. 1997 Oct;5(10):399-405 [9351176.001]
  • [Cites] Nature. 1998 Jan 1;391(6662):86-9 [9422510.001]
  • [Cites] Blood Cells Mol Dis. 1998 Jun;24(2):114-23 [9628848.001]
  • [Cites] Antivir Chem Chemother. 1998 May;9(3):275-82 [9875407.001]
  • [Cites] Transplantation. 1999 Mar 15;67(5):765-7 [10096538.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1485-91 [10197618.001]
  • [Cites] J Virol. 1999 May;73(5):4181-7 [10196314.001]
  • [Cites] Curr Opin Immunol. 1999 Aug;11(4):365-70 [10448133.001]
  • [Cites] J Natl Cancer Inst. 2004 Nov 17;96(22):1691-702 [15547182.001]
  • [Cites] J Virol. 2005 Nov;79(22):13984-92 [16254334.001]
  • [Cites] J Virol. 2005 Nov;79(22):13993-4003 [16254335.001]
  • [Cites] Mol Cancer Ther. 2005 Dec;4(12):2037-44 [16373719.001]
  • [Cites] Transplantation. 1998 Dec 27;66(12):1604-11 [9884246.001]
  • [Cites] J Gen Virol. 2002 Dec;83(Pt 12):2995-8 [12466475.001]
  • [Cites] Cancer Cell. 2003 Jan;3(1):23-36 [12559173.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):965-71 [12615710.001]
  • [Cites] N Engl J Med. 1985 Dec 19;313(25):1564-71 [2999595.001]
  • [Cites] Int J Cancer. 1986 Mar 15;37(3):367-73 [3005176.001]
  • [Cites] J Virol. 1986 Nov;60(2):569-73 [3021990.001]
  • [Cites] Lancet. 1986 Nov 15;2(8516):1122-4 [2877273.001]
  • [Cites] Infection. 1987;15 Suppl 1:S14-20 [3036715.001]
  • [Cites] J Virol. 1987 Oct;61(10):3120-32 [3041034.001]
  • [Cites] Antimicrob Agents Chemother. 1987 Sep;31(9):1431-3 [2823699.001]
  • [Cites] Antimicrob Agents Chemother. 1988 Jul;32(7):1068-72 [2847639.001]
  • [Cites] J Virol. 1989 Jan;63(1):445-9 [2462063.001]
  • [Cites] J Virol. 1990 Jun;64(6):3033-41 [2159561.001]
  • [Cites] J Exp Med. 1990 Jul 1;172(1):61-8 [2162905.001]
  • [Cites] J Am Acad Dermatol. 1990 Jun;22(6 Pt 2):1278-82 [2163409.001]
  • [Cites] Science. 1990 Nov 9;250(4982):830-2 [2173142.001]
  • [Cites] J Virol. 1991 Jun;65(6):2868-74 [1851858.001]
  • (PMID = 18528464.001).
  • [ISSN] 0065-7778
  • [Journal-full-title] Transactions of the American Clinical and Climatological Association
  • [ISO-abbreviation] Trans. Am. Clin. Climatol. Assoc.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA058853; United States / NCI NIH HHS / CA / R01 CA066519; United States / NCI NIH HHS / CA / R01-CA58853; United States / NCI NIH HHS / CA / R01-CA66519
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antiviral Agents; 0 / IL6 protein, human; 0 / Interleukin-6
  • [Number-of-references] 82
  • [Other-IDs] NLM/ PMC1500921
  •  go-up   go-down


14. Tabata M, Satake A, Okura N, Yamazaki Y, Toda A, Nishioka K, Tanaka H, Chin M, Itsukuma T, Yamaguchi M, Misawa M, Kai S, Hara H: Long-term outcome after allogeneic bone marrow transplantation for hematological malignancies with non-remission status. Results of a single-center study of 24 patients. Ann Hematol; 2002 Oct;81(10):582-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To investigate the problem of allogeneic bone marrow transplantation (allo-BMT) for advanced stage patients, we retrospectively analyzed 24 consecutive patients who underwent allo-BMT in the non-remission stage.
  • Twenty-four patients (19 males and 5 females) with acute leukemia, chronic myelogenous leukemia, and malignant lymphoma underwent allo-BMT.
  • There were eight cases of acute myelogenous leukemia (AML), six cases acute lymphocytic leukemia (ALL), nine cases of chronic myelogenous leukemia (CML), and one case of Burkitt's lymphoma.
  • Our important problem is to decrease transplantation-related deaths in allo-BMT during the non-remission stage, and longer survival can be expected with better pretreatment and prophylaxis for GVHD.
  • In addition, the selection of the source of hematopoietic stem cell transplantation at an optimal time is considered to be another problem to be approached.
  • [MeSH-major] Bone Marrow Transplantation. Drug Resistance, Neoplasm. Hematologic Neoplasms / therapy

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12424540.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


15. Lim ST, Karim R, Nathwani BN, Tulpule A, Espina B, Levine AM: AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol; 2005 Jul 1;23(19):4430-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy.
  • PURPOSE: To compare outcomes of patients with HIV-Burkitt's lymphoma (HIV-BL) and HIV-diffuse large-cell lymphoma (HIV-DLCL) after treatment with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or M-BACOD (methotrexate, bleomycin, cyclophosphamide, etoposide) in pre-highly active antiretroviral therapy (HAART) versus HAART eras.
  • PATIENTS AND METHODS: Three hundred sixty-three patients with AIDS-related lymphoma diagnosed from 1982 to 2003 were reviewed retrospectively, including 262 in the pre-HAART (HIV-BL, 117; HIV-DLCL, 145) and 101 in the HAART era (HIV-BL, 18; HIV-DLCL, 83).
  • RESULTS: There were no significant differences between groups in terms of age, sex, history of injection drug use, prior AIDS, lactate dehydrogenase level, and disease stage at diagnosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Bleomycin / therapeutic use. Burkitt Lymphoma / mortality. Cyclophosphamide / therapeutic use. Dexamethasone / therapeutic use. Doxorubicin / therapeutic use. Leucovorin / therapeutic use. Lymphoma, AIDS-Related / mortality. Lymphoma, Large B-Cell, Diffuse / mortality. Methotrexate / therapeutic use. Prednisone / therapeutic use. Vincristine / therapeutic use


16. Astrow AB, Tarabay G, Salerno VE, Cook WA, Lin R, Lascher S, Li Z, Mazumder A, Halperin I, Cho J, Jaffar Z, McLaughlin M, Blum RH, Kempin SJ: Long-term survival in patients with human immunodeficiency virus-associated small non-cleaved cell lymphoma: the role for short course intensive chemotherapy. Hematol Oncol; 2003 Sep;21(3):131-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival in patients with human immunodeficiency virus-associated small non-cleaved cell lymphoma: the role for short course intensive chemotherapy.
  • While intensive chemotherapy is recommended for the treatment of non-HIV related adult small non-cleaved lymphoma (SNCL), including Burkitt's and Burkitt-like lymphoma, optimal treatment for patients with HIV-associated SNCL is not known.
  • Of this cohort 39% were complete responders (CR) and 36% were long-term lymphoma-free survivors.
  • Short course intensive chemotherapy (McMaster) was administered to 23 patients; 17 received less intensive conventional combination chemotherapy; and four received single-agent chemotherapy or no treatment.
  • Of the stage I patients, 75% (6/8) achieved long-term CR with half being treated conventionally.
  • Conventional chemotherapy may be curative for early stage HIV-SNCL.
  • [MeSH-major] Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / mortality
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / virology. Cohort Studies. Female. Humans. Male. Middle Aged. Registries. Remission Induction. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Small non-cleaved cell lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 John Wiley & Sons, Ltd.
  • (PMID = 14579241.001).
  • [ISSN] 0278-0232
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


17. Straus DJ: Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma. Recent Results Cancer Res; 2002;159:143-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma.
  • Chemotherapy regimens similar to those used for non-Hodgkin's lymphoma (NHL) not associated with human immunodeficiency virus (HIV) infection have been used for patients with HIV-associated NHL with less success.
  • In univariate and multivariate analyses of 21 pretreatment features of patients in this trial, four factors emerged as adversely prognostic with respect to survival: age >35 years, intravenous drug use, CD4 counts < 100/mm3 and stage III/IV disease.
  • In an analysis using the proportional hazards model, a "favorable" group was defined by patients with 0 or 1 adverse factor (median survival 46 weeks, survival at 144 weeks 29.5%) as compared with an unfavorable group with 3 or 4 adverse factors (median survival 18 weeks, survival at 144 weeks 0).
  • A recent trial of the AIDS Malignancy Consortium found that low-dose chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone: CHOP) and standard-dose chemotherapy had similar response rates, acceptable toxicity and minimal alterations in cyclophosphamide, doxorubicin and indinavir pharmacokinetics in HIV-associated lymphoma patients also on HAART (stavudine, lamivudine and indinavir).
  • There is a suggestion that Burkitt-type lymphomas may tend to occur in HIV-infected patients with relatively well preserved immune function and CD4 cell counts.
  • Recent results from our institution suggest that similar outcomes are achievable with intensive chemotherapy in patients with Burkitt's lymphomas with or without HIV infection.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, AIDS-Related / therapy

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11785838.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Review
  • [Publication-country] Germany
  • [Number-of-references] 19
  •  go-up   go-down


18. Lam MS: Treatment of Burkitt's lymphoma during pregnancy. Ann Pharmacother; 2006 Nov;40(11):2048-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of Burkitt's lymphoma during pregnancy.
  • OBJECTIVE: To report a case of both successful maternal treatment outcome and normal fetal outcome in a patient who was diagnosed with Burkitt's lymphoma (BL) and aggressively treated with 6 different chemotherapy agents during the second and third trimesters of pregnancy.
  • CASE SUMMARY: A 21-year-old white woman was diagnosed with stage II BL of the head and neck at 26 weeks' gestation.
  • DISCUSSION: The prognosis of BL depends on the stage at diagnosis, as well as treatment aggressiveness.
  • Previous reports indicate that most patients diagnosed with BL during pregnancy received either no treatment or only one chemotherapy agent, and the majority ultimately died of rapidly progressive diseases.
  • The fetal outcomes seem to depend primarily on the time of exposure to chemotherapy and/or radiation, doses, specific chemotherapy agent given, and frequency of treatment during pregnancy.
  • [MeSH-major] Burkitt Lymphoma / drug therapy. Pregnancy Complications, Neoplastic / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Female. Humans. Ifosfamide / therapeutic use. Infant, Newborn. Male. Methotrexate / therapeutic use. Pregnancy. Registries. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Pregnancy.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17062832.001).
  • [ISSN] 1542-6270
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate; ANAVACYM protocol; IVAC protocol
  •  go-up   go-down


19. Othieno-Abinya NA, Abwao HO, Maina JM, Nyabola LO, Opiyo A, Njuguna E, Ndege P, Musibi A: Non-Hodgkin's lymphomas at Kenyatta the National Hospital Nairobi in the 1990's. East Afr Med J; 2004 Sep;81(9):450-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Forty one per cent were not properly classified histologically, seventy patients out of 190 evaluable (36.8%) had stages IVA and IVB disease at diagnosis.
  • Up to 57.1% of cases of Burkitt's lymphoma tested positive for HIV infection.
  • Standard treatment was offered to the majority of patients, and those who could afford to purchase the medicines stood good chance of achieving complete remission.
  • Poor performance status at diagnosis correlated with shorter follow-up durations and early stage disease correlated with longer follow-up durations.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Kenya / epidemiology. Lymphoma, AIDS-Related / diagnosis. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / epidemiology. Male. Middle Aged. Prednisolone / administration & dosage. Retrospective Studies. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15626054.001).
  • [ISSN] 0012-835X
  • [Journal-full-title] East African medical journal
  • [ISO-abbreviation] East Afr Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Kenya
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


20. Di Nicola M, Carlo-Stella C, Mariotti J, Devizzi L, Massimino M, Cabras A, Magni M, Matteucci P, Guidetti A, Gandola L, Gianni AM: High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt's lymphoma in adults. Br J Haematol; 2004 Sep;126(6):815-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt's lymphoma in adults.
  • A very short, intensive paediatric chemotherapy programme was tested in a consecutive monoinstitutional group of 22 adult Burkitt's lymphoma (BL) patients.
  • PATIENT CHARACTERISTICS: median age, 35.5 (range 18-76) years; Ann Arbor stage I-II/III-IV, 11/11; bulky disease, 15 patients; LDH > or = 460 U/l, 11 patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Disease Progression. Doxorubicin / administration & dosage. Drug Administration Schedule. Female. Humans. Leucovorin / administration & dosage. Male. Methotrexate / administration & dosage. Middle Aged. Retrospective Studies. Salvage Therapy. Survival Rate. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15352985.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


21. Spreafico F, Massimino M, Luksch R, Casanova M, Cefalo GS, Collini P, Ferrari A, Polastri D, Terenziani M, Gasparini M, Fossati-Bellani F: Intensive, very short-term chemotherapy for advanced Burkitt's lymphoma in children. J Clin Oncol; 2002 Jun 15;20(12):2783-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive, very short-term chemotherapy for advanced Burkitt's lymphoma in children.
  • PURPOSE: To improve the 63% event-free survival (EFS) achieved before 1986 in Murphy's stage III to IV Burkitt's lymphoma (BL), both chemotherapy and supportive care were intensified.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Central Nervous System Neoplasms / secondary. Child. Child, Preschool. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Disease-Free Survival. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Infusions, Intravenous. Injections, Spinal. Male. Methotrexate / administration & dosage. Palliative Care. Prognosis. Risk Factors. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12065554.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


22. Kiromat M, Vince JD, Oswyn G, Tefuarani N: The management of children with cancer in Papua New Guinea: a review of children with cancer at Port Moresby General Hospital. P N G Med J; 2004 Sep-Dec;47(3-4):138-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The management of children with cancer in Papua New Guinea: a review of children with cancer at Port Moresby General Hospital.
  • In the period of three and a half years between January 1998 and June 2001, 64 children with cancer were seen at the Paediatric Unit of Port Moresby General Hospital (PMGH).
  • Lymphoma, with Burkitt's lymphoma predominating, was as common as leukaemia.
  • 20 (31%) of the children presented either at an advanced stage of disease or with cancer associated with a poor prognosis with available treatment, and were not offered curative treatment.
  • At review 5 years after the start of the study 19 of the 20 children not offered treatment were known to have died and the outcome for 1 was unknown.
  • Significant problems were encountered in patient treatment.
  • Infections occurred in 74% of treated children and drug shortages were experienced in 26%.
  • The substantial problems faced by the families included marital discord, major financial hardship and, for those referred from other provinces whose children died, major delays and difficulties in repatriation.
  • Appropriate drug regimens, readily available drugs, ongoing advice and data collection should be coordinated through a central source.
  • [MeSH-minor] Child. Developed Countries. Female. Hospitals, General. Humans. Male. Papua New Guinea / epidemiology. Registries

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16862938.001).
  • [ISSN] 0031-1480
  • [Journal-full-title] Papua and New Guinea medical journal
  • [ISO-abbreviation] P N G Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Papua New Guinea
  •  go-up   go-down






Advertisement